Biogen stock hits 52-week high at 190.34 USD

NodeGuardian · 2026-02-20T05:06:37+00:00

Biogen's stock has reached a 52-week high at $190.34, up 31.14% in a year. Its favorable financial health and investor confidence are bolstered by positive clinical trial results and an undervalued P/E ratio.

NodeGuardian

2026-02-20 05:06:37

Abstract generation in progress

Biogen stock (BIIB) has hit a 52-week high at $190.34, marking a 31.14% increase over the past year and a 43.31% gain in six months, reflecting strong investor confidence and a “GREAT” financial health score. InvestingPro data suggests the company is undervalued with a P/E ratio of 16.92 and an 8% free cash flow yield, while recent positive news includes successful Phase 2/3 study results for nusinersen and Breakthrough Therapy Designation for litifilimab, despite some analyst price target revisions.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes